Rabbit ATG

Phase 3Small molecule

Novartis

Rabbit ATG is one of 102 small molecule programs targeting Kidney Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Severe Aplastic AnemiaUnknown status

Fanconi AnemiaRecruiting

Sickle Cell DiseaseRecruiting

Kidney TransplantPreclinical

Active, not recruiting

Severe Aplastic AnemiaPhase 3

Unknown status

Fanconi AnemiaPhase 2

Recruiting

Sickle Cell DiseasePhase 2

Recruiting

Competition

Competitive Landscape

114 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Ultomiris

AstraZeneca

Phase 3

1 2

Soliris

AstraZeneca

Phase 2

10 3

Remodulin

United Therapeutics

Phase 2

1 4

Biological/vaccine

Vertex Pharmaceuticals

Phase 3

1 5

Felzartamab

Biogen

Phase 3

1 6

Rabbit ATG

Novartis

Phase 3

1 7

Zemplar

AbbVie

Preclinical

2 8

Cysteine Hydrochloride

Novartis

Preclinical

1 9

Sensipar

Amgen

Preclinical

1 10

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Sickle Cell Disease

NCT05736419

Q3 2028

Phase 2Recruiting

Severe Aplastic Anemia

NCT02828592

Q4 2028

Phase 2Recruiting

Fanconi Anemia

NCT02143830

Q2 2036

Phase 2Recruiting

Severe Aplastic Anemia

NCT06412497

Clinical

Trials by Indication[1]

Severe Aplastic Anemia3 trials

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT06412497·60 enrolled

ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia

Unknown status·JJinan Military General Hospital·Phase 4·NCT02838992·130 enrolled

A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor

Recruiting·NNorthside Hospital, Inc.·Phase 2·NCT02828592·20 enrolled

Sickle Cell Disease2 trials

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05736419·24 enrolled

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease. (BMTCTN1507)

Completed·MMedical College of Wisconsin·Phase 2·NCT03263559·95 enrolled

Fanconi Anemia1 trial

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Recruiting·—·Phase 2·NCT02143830·70 enrolled

Myeloid1 trial

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

Completed·—·Phase 1·NCT02916979·20 enrolled

Kidney Transplant1 trial

Pediatric Induction Therapy in Kidney Transplantation

Completed·GGang Chen··NCT06087003·958 enrolled

6 more indications

Toxicity1 trial

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05293509

Efficacy and Safety1 trial

Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

Unknown status·—·Phase 2·NCT05214066·60 enrolled

Aplastic Anemia1 trial

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Completed· Novartis logo

Novartis·Phase 2·NCT02404025·10 enrolled

Hematologic Malignancies1 trial

Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT01745913·2 enrolled

Malignant Disease1 trial

Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038857·29 enrolled

Hematological Malignancies1 trial

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Terminated·—·Phase 2·NCT00593554·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Rabbit ATG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rabbit ATG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rabbit ATG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Rabbit ATG

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2028

Q4 2028

Q2 2036

Trials by Indication[1]

Severe Aplastic Anemia3 trials

Sickle Cell Disease2 trials

Fanconi Anemia1 trial

Myeloid1 trial

Kidney Transplant1 trial

Toxicity1 trial

Efficacy and Safety1 trial

Aplastic Anemia1 trial

Hematologic Malignancies1 trial

Malignant Disease1 trial

Hematological Malignancies1 trial

References

Drug Info

Quick Facts

Related News